Du K, Huang H
Transl Oncol. 2024; 52():102247.
PMID: 39693719
PMC: 11722911.
DOI: 10.1016/j.tranon.2024.102247.
Nicolini A, Rossi G, Ferrari P
Front Immunol. 2024; 14:1225175.
PMID: 38332913
PMC: 10850262.
DOI: 10.3389/fimmu.2023.1225175.
Du K, Huang H
Front Immunol. 2023; 14:1275999.
PMID: 37942332
PMC: 10628240.
DOI: 10.3389/fimmu.2023.1275999.
Sasso J, Tenchov R, Bird R, Iyer K, Ralhan K, Rodriguez Y
Bioconjug Chem. 2023; 34(11):1951-2000.
PMID: 37821099
PMC: 10655051.
DOI: 10.1021/acs.bioconjchem.3c00374.
Zhu X, Wu Y, Liao L, Huang W, Yuan L, Huang J
Int J Gen Med. 2023; 16:4235-4248.
PMID: 37745137
PMC: 10516127.
DOI: 10.2147/IJGM.S414270.
Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.
Huang C, Lu H, Shyr C
Am J Cancer Res. 2023; 13(6):2285-2306.
PMID: 37424801
PMC: 10326576.
Biomimetic nanoparticles for tumor immunotherapy.
Yu H, Wu M, Chen S, Song M, Yue Y
Front Bioeng Biotechnol. 2022; 10:989881.
PMID: 36440446
PMC: 9682960.
DOI: 10.3389/fbioe.2022.989881.
Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma.
Li Q, Shen Z, Shen Y, Deng H, Shen Y, Wang J
J Clin Lab Anal. 2022; 36(6):e24484.
PMID: 35561269
PMC: 9169191.
DOI: 10.1002/jcla.24484.
Management of Immune Checkpoint Inhibitor Toxicities.
Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A
Cancer Manag Res. 2020; 12:9139-9158.
PMID: 33061607
PMC: 7533913.
DOI: 10.2147/CMAR.S218756.
Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
Shin J, Phelan P, Gjoerup O, Bachovchin W, Bullock P
Protein Expr Purif. 2020; 177:105766.
PMID: 32987122
PMC: 7518118.
DOI: 10.1016/j.pep.2020.105766.
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.
Chen J, Liu H, Jehng T, Li Y, Chen Z, Lee K
Cancers (Basel). 2019; 11(12).
PMID: 31805690
PMC: 6966557.
DOI: 10.3390/cancers11121909.
Biomimetic Nanoparticle Vaccines for Cancer Therapy.
Kroll A, Jiang Y, Zhou J, Holay M, Fang R, Zhang L
Adv Biosyst. 2019; 3(1):e1800219.
PMID: 31728404
PMC: 6855307.
DOI: 10.1002/adbi.201800219.
Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X, Zeng T, Lin J, Zhang Q, Cheng H, Fang S
Cancer Biol Ther. 2019; 21(2):130-138.
PMID: 31690181
PMC: 7012106.
DOI: 10.1080/15384047.2019.1670520.
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect.
Du Y, Jin Y, Sun W, Fang J, Zheng J, Tian J
Eur Radiol. 2018; 29(8):4294-4302.
PMID: 30506221
PMC: 6610275.
DOI: 10.1007/s00330-018-5814-3.
The era of immunogenomics/immunopharmacogenomics.
Zewde M, Kiyotani K, Park J, Fang H, Yap K, Yew P
J Hum Genet. 2018; 63(8):865-875.
PMID: 29785006
DOI: 10.1038/s10038-018-0468-1.
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.
Almagro J, Daniels-Wells T, Perez-Tapia S, Penichet M
Front Immunol. 2018; 8:1751.
PMID: 29379493
PMC: 5770808.
DOI: 10.3389/fimmu.2017.01751.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L
Oncoimmunology. 2017; 6(12):e1371896.
PMID: 29209572
PMC: 5706611.
DOI: 10.1080/2162402X.2017.1371896.
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M, Yao L, Cheng M, Cai D, Martinek J, Pan C
FASEB J. 2017; 32(3):1537-1549.
PMID: 29146734
PMC: 5892726.
DOI: 10.1096/fj.201700740R.
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.
Dine J, Gordon R, Shames Y, Kasler M, Barton-Burke M
Asia Pac J Oncol Nurs. 2017; 4(2):127-135.
PMID: 28503645
PMC: 5412150.
DOI: 10.4103/apjon.apjon_4_17.
Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?.
Kawashima H, Kimura Y
J Kidney Cancer VHL. 2017; 2(2):55-63.
PMID: 28326259
PMC: 5345540.
DOI: 10.15586/jkcvhl.2015.24.
